BLA 761196 · Adc Therapeutics SA
Zynlonta
Loncastuximab Tesirine-Lpyl · Injection
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Apr 23, 2021: To treat certain types of relapsed or refractory large B-cell lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Apr 23, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
35
2 Phase 3, 13 recruiting
FAERS reports
410
308 serious, 146 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2026.
ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. ( 1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- ZYNLONTA · LONCASTUXIMAB TESIRINE-LPYL 10MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Loncastuximab Tesirine" as an intervention, any sponsor and status, largest first.
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaPivotal-lookingActive, not recruiting
ADC Therapeutics S.A.Industry
NCT04384484 · 440 participants · Start Sep 16, 2020 · Primary completion Mar 31, 2026
Drug: Loncastuximab Tesirine; Rituximab and 2 more · For: Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Sites: La Jolla, California; Redlands, California; Whittier, California · 144 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07308132 · 340 participants (planned) · Start Jan 20, 2026 · Primary completion Aug 31, 2028
Drug: JNJ-95566692; JNJ-87801493 and 10 more · For: Lymphoma, Non-Hodgkin
Sites: Clayton, Australia; Melbourne, Australia; North Ryde, Australia · 19 sites in all
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT05991388 · 210 participants (planned) · Start May 2, 2024 · Primary completion May 1, 2031
Drug: Odronextamab; Loncastuximab tesirine and 7 more · For: B-cell Non Hodgkin Lymphoma
Sites: Sydney, Australia; Brisbane, Australia; Perth, Australia · 11 sites in all
ADC Therapeutics S.A.Industry
NCT02669017 · 183 participants · Start Mar 2016 · Primary completion Feb 21, 2019
Drug: ADCT-402 · For: Non-Hodgkin Lymphoma; Burkitt's Lymphoma; Chronic Lymphocytic Leukemia and 6 more
Sites: La Jolla, California; Atlanta, Georgia; St Louis, Missouri · 11 sites in all
ADC Therapeutics S.A.Industry
NCT04970901 · 154 participants · Start Jun 17, 2022 · Primary completion Mar 31, 2027
Drug: Loncastuximab Tesirine; Polatuzumab Vedotin and 3 more · For: B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
Sites: Clovis, California; San Diego, California; Miami, Florida · 40 sites in all
ADC Therapeutics S.A.Industry
NCT03589469 · 145 participants · Start Aug 1, 2018 · Primary completion May 24, 2020
Drug: Loncastuximab tesirine · For: Diffuse Large B-Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent
Sites: Duarte, California; Fountain Valley, California; La Jolla, California · 37 sites in all
ADC Therapeutics S.A.Industry
NCT03684694 · 136 participants · Start Dec 1, 2018 · Primary completion Nov 8, 2022
Drug: Loncastuximab Tesirine; Ibrutinib · For: Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma
Sites: Orange, California; Redlands, California; Miami, Florida · 35 sites in all
Universität MünsterAcademic, hospital or other
NCT07197307 · 120 participants (planned) · Start Oct 31, 2025 · Primary completion Apr 30, 2030
Drug: Loncastuximab Tesirine and Epcoritamab · For: Aggressive Diffuse Large B-cell Lymphoma; High-grade B-cell Lymphoma (HGBL); Follicular Lymphoma (FL) Grade 3B
Sites: Aachen, Germany; Augsburg, Germany; Berlin, Germany · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death69
- disease progression33
- rash32
- pleural effusion24
- fatigue22
- photosensitivity reaction21
- neutropenia18
- anaemia16
- thrombocytopenia15
- covid-1914
- oedema14
- off label use14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 26 |
| 2022 | 84 |
| 2023 | 77 |
| 2024 | 62 |
| 2025 | 68 |
| 2026 | 90 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zynlonta (Loncastuximab Tesirine-Lpyl)
2024 spending
$288K
Beneficiaries
n/a
11 claims
Per beneficiary
n/a
$26,187.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $823,081 |
| 2023 | $674,926 |
| 2024 | $288,058 |
Part B: Zynlonta (Loncastuximab Tesirine-Lpyl) · HCPCS J9359
2024 spending
$27.3M
Beneficiaries
243
976 claims
Per beneficiary
$112,232
2024 ASP limit $203.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $23,389,056 |
| 2023 | $29,146,424 |
| 2024 | $27,272,265 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, et al. · Haematologica 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, et al. · Lancet Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.
Alderuccio JP, Alencar AJ, Schatz JH, et al. · Lancet Haematol 2025 · Clinical Trial, Phase II
- Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Khan A, Habib H, Butt AI, et al. · Syst Rev 2026 · Systematic Review, Meta-Analysis
- Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
Lin N, Sun X, Zhou H, et al. · Haematologica 2025 · Clinical Trial, Phase II, Multicenter Study
- Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ࣙ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison.
Wilson K, Chiodi F, Paine A, et al. · Adv Ther 2025 · Comparative Study, Systematic Review
Sponsor: Adc Therapeutics SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.